Their project, OrigamiDoc, earned them a significant $723,000 funding to support their groundbreaking work in pharmaceutical security. Their innovative solution focuses on Nano Origami DNA technology to develop a targeted drug for the treatment of Takayasu Arteritis, an inflammatory disease. The project aims to move into clinical trials and commercial production, representing a promising leap in pharmaceutical research and security.
This incredible achievement not only highlights their academic excellence but also showcases the global impact MSA graduates are making in advancing healthcare solutions. Their success is a testament to MSA’s commitment to fostering creativity, innovation, and practical applications in science and technology, which was under the academic supervision of the faculty member Dr. Hossam Taha.
We are immensely proud of Mennat Allah and Noorhan for their outstanding contribution to the future of pharmaceutical research and wish them continued success in their endeavors.